Cingulate (CING) Stock Price, News & Analysis

Company Overview

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company is developing pharmaceutical products intended to address challenges associated with existing therapies, including the need for sustained symptom control and convenient once-daily dosing.

Cingulate’s lead product candidate, CTx-1301, is designed as a once-daily treatment for ADHD using its proprietary Precision Timed Release (PTR) drug-delivery platform. The platform is intended to provide the release of multiple doses of medication at predetermined times during the day, potentially supporting extended therapeutic coverage from a single dose. Cingulate has also identified additional product candidates, including CTx-1302, for development in the ADHD market.

Based in Kansas City, Kansas, Cingulate conducts its research and clinical-development activities primarily in the United States. The company has no broadly commercialized products and remains focused on advancing its pipeline through clinical development and regulatory review. Cingulate was co-founded and is led by Shane J. Schaffer, who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $4.77 to $4.98
• 50-Day Range: $4.75 to $5.87
• 52-Week Range: $3.16 to $11.89
• Volume: 27,812 shs
• Average Volume: 94,997 shs
• Market Capitalization: $71.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Moderate Buy

Cingulate Stock Analysis - MarketRank™

Cingulate scored higher than 38% of companies evaluated by MarketBeat, and ranked 690th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cingulate has a consensus price target of $27.00, representing about 452.1% upside from its current price of $4.89.

Amount of Analyst Coverage

Cingulate has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cingulate are expected to grow in the coming year, from ($2.19) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cingulate is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cingulate is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cingulate has a P/B Ratio of 15.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.49% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 10.49, which indicates bearish sentiment.

Change versus previous month

Short interest in Cingulate has recently decreased by 11.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cingulate does not currently pay a dividend.

Dividend Growth

Cingulate does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cingulate this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cingulate insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.30% of the stock of Cingulate is held by insiders.

Percentage Held by Institutions

41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CING
• CIK: 1862150
• Web: www.cingulate.com
• Phone: 913-942-2300
• Fax: N/A
• Employees: 14
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Cingulate: $27.00
• High Price Target: $52.00
• Low Price Target: $9.00
• Potential Upside/Downside: +452.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.40%
• Return on Assets: -128.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.50

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 15.77

Miscellaneous

• Outstanding Shares: 14,542,000
• Free Float: 13,771,000
• Market Cap: $71.11 million
• Optionable: Not Optionable
• Beta: -0.88